Junkins-Hopkins JM - Search Results

1

Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH. Kim EJ, et al. J Clin Invest. 2005 Apr;115(4):798-812. doi: 10.1172/JCI24826. J Clin Invest. 2005. PMID: 15841167 Free PMC article. Review.

2

High clinical response rate with multimodality immunomodulatory therapy for Sézary syndrome.

Richardson SK, Lin JH, Vittorio CC, Kim EJ, Yoon JS, Junkins-Hopkins J, Rook AH. Richardson SK, et al. Clin Lymphoma Myeloma. 2006 Nov;7(3):226-32. doi: 10.3816/CLM.2006.n.063. Clin Lymphoma Myeloma. 2006. PMID: 17229339 Clinical Trial.

3

Primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma.

Gormley RH, Hess SD, Anand D, Junkins-Hopkins J, Rook AH, Kim EJ. Gormley RH, et al. J Am Acad Dermatol. 2010 Feb;62(2):300-7. doi: 10.1016/j.jaad.2009.02.035. Epub 2009 Nov 26. J Am Acad Dermatol. 2010. PMID: 19944484 Review.

4

Total skin electron beam therapy may be associated with improvement of peripheral blood disease in Sézary syndrome.

Introcaso CE, Micaily B, Richardson SK, Junkins-Hopkins JM, Yoon JS, Kim EJ, Vittorio CC, Rook AH. Introcaso CE, et al. J Am Acad Dermatol. 2008 Apr;58(4):592-5. doi: 10.1016/j.jaad.2007.12.016. Epub 2008 Feb 4. J Am Acad Dermatol. 2008. PMID: 18249469

5

CD8+ epidermotropic cytotoxic T-cell lymphoma with peripheral blood and central nervous system involvement.

Introcaso CE, Kim EJ, Gardner J, Junkins-Hopkins JM, Vittorio CC, Rook AH. Introcaso CE, et al. Arch Dermatol. 2008 Aug;144(8):1027-9. doi: 10.1001/archderm.144.8.1027. Arch Dermatol. 2008. PMID: 18711076

6

New biologic agents for the treatment of cutaneous T-cell lymphoma.

Vittorio CC, Junkins-Hopkins JM, McGinnis KS, Shapiro M, Wysocka M, Zaki MH, French LE, Rook AH. Vittorio CC, et al. Recent Results Cancer Res. 2002;160:321-8. doi: 10.1007/978-3-642-59410-6_37. Recent Results Cancer Res. 2002. PMID: 12079230 Review.

7

Treatment of stage IA cutaneous T-Cell lymphoma with topical application of the immune response modifier imiquimod.

Suchin KR, Junkins-Hopkins JM, Rook AH. Suchin KR, et al. Arch Dermatol. 2002 Sep;138(9):1137-9. doi: 10.1001/archderm.138.9.1137. Arch Dermatol. 2002. PMID: 12224972 No abstract available.

8

Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.

Shapiro M, Rook AH, Lehrer MS, Junkins-Hopkins JM, French LE, Vittorio CC. Shapiro M, et al. J Am Acad Dermatol. 2002 Dec;47(6):956-61. doi: 10.1067/mjd.2002.124816. J Am Acad Dermatol. 2002. PMID: 12451388 No abstract available.

9

Cytokines and other biologic agents as immunotherapeutics for cutaneous T-cell lymphoma.

Rook AH, Junkins-Hopkins JM, McGinnis KS, Wysocka M, Richardson SK, Budgin JB, Everitts S, Vittorio CC. Rook AH, et al. Adv Dermatol. 2002;18:29-43. Adv Dermatol. 2002. PMID: 12528401 Review.

10

Extracorporeal photopheresis and multimodality immunomodulatory therapy in the treatment of cutaneous T-cell lymphoma.

Richardson SK, McGinnis KS, Shapiro M, Lehrer MS, Kim EJ, Vittorio CC, Junkins Hopkins JM, Rook AH. Richardson SK, et al. J Cutan Med Surg. 2003 Jul-Aug;7(4 Suppl):8-12. doi: 10.1007/s10227-003-5002-0. J Cutan Med Surg. 2003. PMID: 12958701 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

109 results

Search Page

Filters